BNT3214

BioNTech SE · Phase 1 active Small molecule

At a glance

Generic name	BNT3214
Also known as	PM8102
Sponsor	BioNTech SE
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BNT3214 CI brief — competitive landscape report
BNT3214 updates RSS · CI watch RSS
BioNTech SE portfolio CI